Biond Biologics Overview
Biond Biologics is a biotechnology company developing immunotherapies and an intracellular drug delivery platform for the treatment of cancer patients. The company uses biologics targeting novel immune evasion mechanisms, discovered through in-house research utilizing real-world patient and tumor samples. Biond Biologics is developing an intracellular delivery platform for biologics (e.g., antibodies or enzymes) inside cells, allowing the company to drug intracellular targets currently considered "undruggable."
Cumulative Funding Raised Over Time ($)
$5.0M
$22.0MJan 2019
$37.0MNov 2021
Latest News
growth-positive
/PRNewswire/ -- Biond Biologics Ltd. ("Biond" or the "Company"), a private, clinical-stage biopharmaceutical company developing novel immunotherapies for...
Biond Biologics Ltd., a clinical-stage biopharmaceutical company, has launched a Phase 2 study of its novel immunotherapy, BND-22, in combination with anti-PD-1 therapy. The study aims to identify biomarkers related to the mechanism of action and predictive biomarkers for response and resistance in patients with specific cancer types. The study is being conducted in collaboration with MD Anderson Cancer Center and builds on promising results from earlier trials. Biond retains global rights to BND-22 and is focused on advancing it into registrational trials. The company is also developing other innovative therapies targeting novel oncology pathways.
Product StagePartners
growth-positive
Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial
Biond Biologics has announced that the first patients have been dosed in a phase 1 clinical trial evaluating the safety and anti-tumor activity of BND-22, an ILT2 receptor blocking antibody, in combination with pembrolizumab or cetuximab. The trial aims to explore the potential of BND-22 in treating advanced solid tumors. Biond Biologics entered into an exclusive worldwide license agreement with Sanofi for the development and commercialization of BND-22. The agreement stipulates that Biond will lead the phase 1 study, and Sanofi will assume clinical development and commercialization responsibilities thereafter. BND-22 is a humanized IgG4 antibody that targets the ILT2 receptor and has shown promise in preclinical studies. Biond Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer.
PartnersInvestment
growth-positive
Biond Biologics Announces Closing of $15 Million Series C Financing
Biond Biologics has closed a $15 million Series C financing round led by Deep Insight, with participation from new investors such as the Heritage Group and existing investors such as Harel Insurance. The financing will enable Biond to bring its next pre-clinical programs to the clinic. Biond has also entered a strategic collaboration with Sanofi for the development of BND-22, its receptor-blocking antibody, and has other innovative immuno-oncology programs in its pipeline. Biond is focused on developing therapies for novel oncology targets and enabling the intracellular delivery of biologics. The companys INspire platform allows for the delivery of drugs to intracellular targets. Deep Insight invests in deep tech companies and sees Bionds platform as having the potential for significant impact.
Investment
growth-positive
Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
Biond Biologics has announced the dosing of the first patient in the phase 1 clinical trial of BND-22, an ILT2 receptor blocking antibody for the treatment of advanced solid tumors. The trial will evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and exploratory biomarkers of BND-22. The entry of BND-22 into the clinic is a significant milestone for Biond, and the company looks forward to the results of the trial. Biond has an exclusive worldwide license agreement with Sanofi for the development and commercialization of BND-22. Biond is a biopharmaceutical company focused on developing innovative immunotherapies for cancer and a platform for intracellular delivery of biologics.
CustomersPartners
growth-positive
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
Biond Biologics has entered into an exclusive worldwide license agreement with Sanofi for the development and commercialization of BND-22, a humanized IgG4, antagonist antibody targeting the ILT2 receptor for the treatment of solid tumors. Biond will receive a $125 million upfront payment and could receive over $1 billion in milestones and royalty payments. Biond will lead the phase 1a study of BND-22, and Sanofi will take over clinical development and commercialization. BND-22 has shown a broad anti-tumor effect in preclinical studies and a phase 1 study is planned to start in mid-2021. The partnership with Sanofi validates Bionds strategy and creates value for shareholders.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $37M |
| Last funding | $15M |
| Stage | C |
| Rounds | 3 |
| Investors | 6 |
Team Members
8
Employees: 11-50
Web & Social Links
| Website | www.biondbio.com |
Locations
Misgav, Israel
Photos & Videos
No files yet
Biond Biologics Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsCellsTags (9)
pharmaceuticalsimmunologydrug-discoveryoncologyautoimmune-diseasesbiopharmaceuticalcancerpharma-companiesimmunotherapyGeographic Markets
GlobalBiond Biologics Financials
$37M
Total funding
Undisclosed
Capital raised
$15M
Last funding
C
Funding stage
3
Total rounds
6
Investors
Cumulative Funding Raised Over Time ($)
$5.0M
$22.0MJan 2019
$37.0MNov 2021
Private Equity Funding
C Round
Nov 2021
$15M
Deep Insight (Lead)
,
Heritage Group, Harel Insurance & Finance
B Round
Jan 2019
$17M
Harel Insurance & Finance (Lead)
,
Celgene Corporation(Japan), SBI JI Innovation Fund, Israel Biotech Fund
A Round
$5M
Biond Biologics Lifecycle
Cumulative Funding Raised Over Time
$5.0M
$22.0MJan 2019
$37.0MNov 2021
All Events
C Round
Nov 2021
$15M
Deep Insight (Lead)
,
Heritage Group, Harel Insurance & Finance
B Round
Jan 2019
$17M
Harel Insurance & Finance (Lead)
,
Celgene Corporation(Japan), SBI JI Innovation Fund, Israel Biotech Fund
A Round
$5M
Biond Biologics News
9 articles
growth-positive
/PRNewswire/ -- Biond Biologics Ltd. ("Biond" or the "Company"), a private, clinical-stage biopharmaceutical company developing novel immunotherapies for...
Biond Biologics Ltd., a clinical-stage biopharmaceutical company, has launched a Phase 2 study of its novel immunotherapy, BND-22, in combination with anti-PD-1 therapy. The study aims to identify biomarkers related to the mechanism of action and predictive biomarkers for response and resistance in patients with specific cancer types. The study is being conducted in collaboration with MD Anderson Cancer Center and builds on promising results from earlier trials. Biond retains global rights to BND-22 and is focused on advancing it into registrational trials. The company is also developing other innovative therapies targeting novel oncology pathways.
Product StagePartners
growth-positive
Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial
Biond Biologics has announced that the first patients have been dosed in a phase 1 clinical trial evaluating the safety and anti-tumor activity of BND-22, an ILT2 receptor blocking antibody, in combination with pembrolizumab or cetuximab. The trial aims to explore the potential of BND-22 in treating advanced solid tumors. Biond Biologics entered into an exclusive worldwide license agreement with Sanofi for the development and commercialization of BND-22. The agreement stipulates that Biond will lead the phase 1 study, and Sanofi will assume clinical development and commercialization responsibilities thereafter. BND-22 is a humanized IgG4 antibody that targets the ILT2 receptor and has shown promise in preclinical studies. Biond Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer.
PartnersInvestment
growth-positive
Biond Biologics Announces Closing of $15 Million Series C Financing
Biond Biologics has closed a $15 million Series C financing round led by Deep Insight, with participation from new investors such as the Heritage Group and existing investors such as Harel Insurance. The financing will enable Biond to bring its next pre-clinical programs to the clinic. Biond has also entered a strategic collaboration with Sanofi for the development of BND-22, its receptor-blocking antibody, and has other innovative immuno-oncology programs in its pipeline. Biond is focused on developing therapies for novel oncology targets and enabling the intracellular delivery of biologics. The companys INspire platform allows for the delivery of drugs to intracellular targets. Deep Insight invests in deep tech companies and sees Bionds platform as having the potential for significant impact.
Investment
growth-positive
Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
Biond Biologics has announced the dosing of the first patient in the phase 1 clinical trial of BND-22, an ILT2 receptor blocking antibody for the treatment of advanced solid tumors. The trial will evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and exploratory biomarkers of BND-22. The entry of BND-22 into the clinic is a significant milestone for Biond, and the company looks forward to the results of the trial. Biond has an exclusive worldwide license agreement with Sanofi for the development and commercialization of BND-22. Biond is a biopharmaceutical company focused on developing innovative immunotherapies for cancer and a platform for intracellular delivery of biologics.
CustomersPartners
growth-positive
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
Biond Biologics has entered into an exclusive worldwide license agreement with Sanofi for the development and commercialization of BND-22, a humanized IgG4, antagonist antibody targeting the ILT2 receptor for the treatment of solid tumors. Biond will receive a $125 million upfront payment and could receive over $1 billion in milestones and royalty payments. Biond will lead the phase 1a study of BND-22, and Sanofi will take over clinical development and commercialization. BND-22 has shown a broad anti-tumor effect in preclinical studies and a phase 1 study is planned to start in mid-2021. The partnership with Sanofi validates Bionds strategy and creates value for shareholders.
Partners
growth-positive
Biond Biologics Appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate Update
Biond Biologics has appointed Dr. Jerome Zeldis to its Board of Directors. Dr. Zeldis brings extensive clinical development expertise to the company as it develops novel immunotherapies for cancer. Biond is on track to submit an Investigational New Drug Application (IND) for its novel ILT2 receptor blocking antibody, BND-22, in Q4 2020 and initiate a first-in-human clinical trial in Q1 2021. The company aims to deliver innovative medicines to patients and foster collaborations with leading biopharmaceutical companies. Bionds pipeline includes BND-22, a multi-cell checkpoint inhibitor targeting ILT2, and BION-206, an agent for overcoming PD-1 blockade resistance. In addition, Biond is developing a platform for intracellular delivery of biologic agents. The appointment of Dr. Zeldis and progress in clinical development demonstrate positive growth for the company.
Management Changes
growth-positive
Biond Biologics Appoints Immunotherapy Pioneer Alan Korman Ph.D. to Scientific Advisory Board
Biond Biologics has announced that Alan Korman, Ph.D., will join the companys Scientific Advisory Board as its chairman. Dr. Korman is a pioneer in the field of immunotherapy and has contributed immensely to the industrys efforts to target immune evasion mechanisms employed by tumors. His expertise and experience in drug discovery will prove invaluable for Biond as they progress their innovative immuno-oncology programs, including BND-22, their first-in-class, multi-cell checkpoint inhibitor targeting ILT2. With the appointment of Dr. Korman, Bionds Scientific Advisory Board now consists of four members. Biond Biologics is a privately-held Israeli biotech company focused on developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics.
Management Changes
growth-positive
Israeli co Biond Biologics raises $17m
Biond Biologics has closed a $17 million Series B financing round led by Israel Biotech Fund and Harel Insurance & Finance Group. The company, based in Israel, is developing novel immunotherapies for cancer and autoimmune diseases. The funds will be used to move its lead drug candidate into clinical trials and advance the preclinical development of other drugs.
Investment
growth-positive
Pfizer buys rights to BioRap autoimmune drug
BioRap Technologies has signed a collaboration agreement with Pfizer for the development of a drug to treat autoimmune diseases, specifically inflammatory intestinal diseases. The deal is believed to be worth tens of millions of dollars, including royalties. The product, an antibody that activates cells in the immune system to reduce inflammation, has potential applications for various inflammatory diseases. The product is currently undergoing animal trials. BioRap Technologies previously gave another product to GSK for commercialization, which could also generate tens of millions of dollars. The collaboration with Pfizer is a growth-positive move for BioRap Technologies.
PartnersInvestment
Biond Biologics Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 36 |
| Team members | 8 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Biond Biologics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | video or image, markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515445823 |
| Crunchbase | biond-biologics |
| Phone | +97248844337 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-09-13T00:00:00.000Z |
| Created | 2017-02-26T00:00:00.000Z |
| Claimed | Yes |